Skip to content

Transcutaneous auricular vagus nerve stimulation in the treatment of postpartum uterine contraction pain after natural delivery

Observation on the clinical efficacy of transcutaneous auricular vagus nerve stimulation in the treatment of postpartum uterine contraction pain after natural delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001275
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum uterine contraction pain

Interventions

taVNS1Hz group:taVNS1Hz+Routine treatments except analgesia
taVNS20Hz group:taVNS20Hz+Routine treatments except analgesia
sham taVNS group:sham taVNS+Routine treatments except analgesia

Sponsors

The Second Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Natural delivery mother 2.Age >=18 years 3.Gestation period 37 - 42 weeks 4.Single live birth 5.Plan for breastfeeding 6.Capable of cooperating and signing the informed consent form

Exclusion criteria

Exclusion criteria: 1. Use of vacuum extraction or forceps delivery 2. Severe pregnancy-related complications or postpartum complications 3. Presence of uterine or pelvic disorders, such as adenomyosis, pelvic inflammatory disease, etc. 4. Presence of psychological disorders or psychiatric illnesses, such as manic disorder, schizophrenia, etc., with abnormal emotions, comprehension, or expression abilities 5. Severe central nervous system or internal/surgical diseases, such as epilepsy, rheumatic/immune diseases, coagulation disorders, etc. 6. Long-term use of analgesic medications 7. History of anxiety, depression, or insomnia 8. Ear deformities, sensory impairments, other ear disorders, or contraindications for taVNS use 9. Allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) or contraindications for their use, such as gastric ulcers, gastrointestinal bleeding, or perforation 10. Recent receipt of similar treatments or participation in other studies

Design outcomes

Primary

MeasureTime frame
The proportion of cases with Visual Analog Scale (VAS) score for uterine contractions = 4;

Secondary

MeasureTime frame
Proportion of patients with uterine contraction pain VAS score = 4 at other time points;The frequency, duration, number of occurrences with VAS >= 4, and peak value of uterine contractions pain episodes;Number, duration, number of episodes with VAS =4, and peak of uterine contraction pain during oxytocin use.;The time when the contractions pain completely disappears;lactation yield;The time of first lactation, the number of breastfeeding sessions, and the peak intensity of uterine contractions during breastfeeding.;Amount of vaginal bleeding;Depression score;Anxiety score;Sleep score;Other scores for physical pain;The number of people using remedial analgesic drugs;ECG (electrocardio);

Countries

China

Contacts

Public ContactTaipin Guo

Yunnan University of Chinese Medicine

gtphncs@126.com+86 184 8727 2658

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 8, 2026